A Study of the MIND Diet for Persons With Multiple Sclerosis

This study is looking at how a special eating plan, called the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet, might affect brain health and symptoms in people with multiple sclerosis (MS). You would be randomly assigned to either follow the MIND diet for one year with support, or continue your usual diet while receiving MS-related education. Researchers will measure changes in a blood marker called neurofilament light chain (NfL), which can indicate nerve damage, at the beginning, 6 months, and 12 months. To join, you need to be between 18 and 70 years old, have an MS diagnosis, and have a MIND diet score of 8 or less at the start. The study aims to enroll 100 participants, but its current recruitment status is unclear.

Study design
This is an interventional study where participants are randomly assigned to one of two groups. It aims to enroll 100 participants.
What's involved
You would have a baseline visit, a 6-month visit, and a 12-month visit, plus attend small support groups between visits. You would also complete online questionnaires, undergo functional and cognitive assessments, and provide blood and stool samples.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06992115

A Study of the MIND Diet for Persons With Multiple Sclerosis

Recruiting
NAAges 18–70InterventionalTreatment
Icahn School of Medicine at Mount Sinai
~100 participants
Updated 2025-10-14 on ClinicalTrials.gov
What's tested:Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) DietSmall Group

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in plasma neurofilament light chain (NfL)
Measured over Baseline, 6-months, and at 12-months
Multiple Sclerosis
1 sites across 1 states
New York1
  • Ilana B Katz Sand, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 18-70 years, inclusive
MS diagnosis, on any treatment (including no treatment)
MIND diet score of ≤8 at baseline
NfL parameters determined by age

Exclusion

Diagnosis of an additional neurodegenerative disease (e.g. Alzheimer's) or other serious neurological condition (e.g. stroke)
Current serious medical condition that could impact the ability to participate or influence study results (e.g. cancer, HIV)
Pregnancy/planning during study period
  • Changes in plasma neurofilament light chain (NfL)Baseline, 6-months, and at 12-months

    Plasma NfL quantification will be reported in units of pg/ml.